Endocrine-Related Cancer

Article	Citations
Acknowledgement to reviewers	98
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	77
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	59
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	58
Celebrating the 80th anniversary of hormone ablation for prostate cancer	54
Acknowledgement to reviewers	51
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	45
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	44
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	43
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	38
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	38
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	33
Update on the genetics of paragangliomas	31
Targeting growth hormone in cancer: future perspectives	30
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	30
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	30
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	30
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	29
Radioiodine treatment: an historical and future perspective	29
Metabolically active brown adipose tissue in PPGL: an observational cohort study	29
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	28
Peptide receptor radionuclide therapy in malignant insulinoma	26
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	25
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	25
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	25

CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	24
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	23
Antitumor immune response is associated with favorable survival in GEP-NEN G3	23
Whole-exome sequencing of rectal neuroendocrine tumors	22
Gender-affirming care and endocrine-related cancers	22
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	22
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	22
Therapy considerations in neuroendocrine prostate cancer: what next?	21
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	21
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	21
Immunotherapy for endocrine tumours: a clinician’s perspective	21
Effect of TSH levels during active surveillance of PTMC according to age	20
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	19
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	19
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	18
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	17
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	17
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	16
From bench to bedside in the sella: translational developments in pituitary tumour genetics	15
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	15
Exploring stem cell biology in pituitary tumors and derived organoids	15
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	14
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	14
Steroid profile in patients with breast cancer and in mice treated with mifepristone	14
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	13
Acknowledgement to reviewers	13
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	13
Acknowledgement to reviewers	13
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	12
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	12
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	12
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	12
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	12
New therapeutic opportunities for women with low-grade serous ovarian cancer	12
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	12
Genetic disorders and insulinoma/glucagonoma	12
Clinical features of plurihormonal pituitary adenoma subtypes	12
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	12
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	12
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	11
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	11
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	11
Non-pituitary GH regulation of the tissue microenvironment	11
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	11
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	11
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	11
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	11

Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	11
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	11
Deiodinases in thyroid tumorigenesis	11
Beyond the three P’s: adrenal involvement in MEN1	11
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	10
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	10
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	10
In memoriam: Charis Eng MD PhD (1962–2024)	10
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	10
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	10
Surrogate molecular classification of LAR breast cancer in routine workflow	10
MicroRNAs as regulators of tumor metabolism	10
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	10
Mendelian randomization to investigate the link between TSH and thyroid cancer	10
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	10
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	9
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	9
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	9
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	9
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	9
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	9
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	9
Precocious puberty due to intracranial germ cell tumors: a case–control study	9
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	8
Risk factors for intraoperative complications in pheochromocytomas	8
Adrenal tumors provide insight into the role of cortisol in NK cell activity	8
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	8
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	8
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	8
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	8
Second-generation hormonotherapy in prostate cancer and bone microenvironment	8
A clinically applicable molecular classification of oncocytic cell thyroid nodules	8
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
Insulinomatosis: new aspects	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	7
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	7
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	7
Inflammation-based score in pediatric adrenocortical carcinoma	7
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	7
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	7
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	7
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	7
Predictors of cancer in patients with endogenous Cushing’s syndrome	6
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	6
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	6
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	6
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	6
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	6
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	6
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	6
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	6
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	6
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	6
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	6
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	6
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	6
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	6
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	6
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
Mechanisms of resistance to RET-directed therapies	5
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	5
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
Development and validation of long-acting recombinant human TSH using SAFA technology	5
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	5
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	5
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	5
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	5

Improved and individualized approach to adrenal surgery	5
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	5
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	5
Second primary cancers and survival among neuroendocrine tumor patients	5
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	4
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	4
The role of membrane mucin MUC4 in breast cancer metastasis	4
Therapeutic inhibition of ATR in differentiated thyroid cancer	4
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Pregnancy-associated breast cancer: the influence of gestational age	4
Targeting androgen receptor signaling: a historical perspective	4
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	4
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	4
Heme-oxygenase-1: A Key Player in Thyroid Carcinoma Development	4
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	4
Autocrine/paracrine growth hormone in cancer progression	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
The role of vitamin D in breast cancer risk and progression	3
PARP inhibitors in advanced prostate cancer: when to use them?	3
Talking about sex: erectile dysfunction in the oncology patient	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	3
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	3
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	3
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	3
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	3
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	3
Aggressive versus indolent insulinomas: new clinicopathological insights	3
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	3
Genomic testing for RET in the clinic: UK and global perspective	3
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	3